ETabductedME
Bluelighter
indeed, thank you all for the excellent thread. i will be sure to pick up mr jansen's book.
MAP: How worried should we be about ketamine neurotoxicity?
JANSEN: The answers are not all in on ketamine and neurotoxicity, but there are grounds for concern regarding chronic use.
Peace,
SG
[ 08 April 2002: Message edited by: Sebastians_ghost ]
Conclusion: "Anyone who has had firsthand contact with enough dissociative users will eventually run across the casualties..."
That was never in contention.
As for my heart not being in the right place, I'll simply repeat what I said at the beginning:
I do not recommend usage of drugs without research and knowledge. I am the first to say one should pay attention to the health data available. However, I am also against bad science, the spread of misinformation, and the use of scare tactics in general. This article is terrible.
Oh, and take a look at the real scientific world. They do, in fact, concern themselves with such trivialities as "measurements" and "control groups". In fact, using those same trivialities the medical world has confirmed the ABSENCE of Olney's Lesions.
I am not willing to accept everything I read, no matter how eminent the writer. If the process is suspect, so are the conclusions. I make my own decisions - you are free to make your own. I would suggest you start a thread marked - "Olney's Lesions - Why You SHOULD be concerned."
[Potent NMDA antagonists] have been associated with acute neurotoxicity in vitro and in vivo, precluding their clinical use
-Zorn
[1] Rothman SM, Olney JW. (1995) Excitotoxicity and the NMDA receptor - still lethal after eight years. TINS 18:57-58.
[2] Olney JW, Farber NB. (1995) NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13:335-45.
[3] Kornhuber J, Weller M. (1997) Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41:135-44.